Literature DB >> 24114422

Carboplatin synergistically triggers the efficacy of photodynamic therapy via caspase 3-, 8-, and 12-dependent pathways in human anaplastic thyroid cancer cells.

Raktim Biswas1, Phil-Sang Chung, Jeong Hwan Moon, Seung-Ha Lee, Jin-Chul Ahn.   

Abstract

Anaplastic thyroid cancer is one of the most aggressive forms of malignancies which grow very rapidly. Several conventional methods have been applied for the treatment of anaplastic thyroid cancer, but most of them were not successful in complete recovery of the patients. Therefore, a combination of two or more conventional modalities is being applied nowadays for the treatment of this type of cancer. In this present study, the combination of photodynamic therapy (PDT) and chemotherapy has been studied in anaplastic thyroid cancer. Human anaplastic thyroid cancer cells FRO were treated with a chemotherapy drug, carboplatin (cis-diammine-1,1-cyclobutanedicarboxyl-ateplatinum II (CBDCA)), and radachlorin-mediated PDT individually and in combination. Several parameters like cytotoxicity assay by MTT, apoptosis study by annexin V and propidium iodide, cell cycle analysis by flow cytometry, confocal microscopic study, and Western blot analysis for different apoptosis-related proteins like Bax, cytochrome c, caspases 3, 9, 8, and 12, etc. were studied to check the efficacy of the combination treatment as well as to find out the mechanism of this enhanced efficacy. Results showed that both PDT and CBDCA can induce apoptosis in FRO cells. However, a synergistic efficacy was observed when the cells were treated with CBDCA and PDT in combination. Changes in mitochondrial membrane potential and an increase in reactive oxygen species generation were observed in combination treatments. The enhanced expression of different apoptotic pathway-related proteins like Bax, cytochrome c, caspase 3, caspase 8, caspase 12, etc. also confirmed the higher efficacy of combination treatment. Therefore, with this combination treatment, not only a higher efficacy can be achieved but also the effective dose of the chemotherapy drug can be reduced, and hence, the adverse side effects of the chemotherapy drugs can also be controlled.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24114422     DOI: 10.1007/s10103-013-1452-9

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  48 in total

1.  Photosensitizer Radachlorin®: Skin cancer PDT phase II clinical trials.

Authors:  Elena V Kochneva; Elena V Filonenko; Elena G Vakulovskaya; Elena G Scherbakova; Oleg V Seliverstov; Nikolay A Markichev; Andrei V Reshetnickov
Journal:  Photodiagnosis Photodyn Ther       Date:  2010-08-14       Impact factor: 3.631

2.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

Authors:  K Kelly; J Crowley; P A Bunn; C A Presant; P K Grevstad; C M Moinpour; S D Ramsey; A J Wozniak; G R Weiss; D F Moore; V K Israel; R B Livingston; D R Gandara
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

3.  Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups.

Authors:  Guo-Pei Yu; James Chun-Lun Li; Daniel Branovan; Steven McCormick; Stimson P Schantz
Journal:  Thyroid       Date:  2010-05       Impact factor: 6.568

4.  Combination with genistein enhances the efficacy of photodynamic therapy against human anaplastic thyroid cancer cells.

Authors:  Jin-Chul Ahn; Raktim Biswas; Phil-Sang Chung
Journal:  Lasers Surg Med       Date:  2012-11-09       Impact factor: 4.025

5.  Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.

Authors:  Kerri S Bevis; Lacey R McNally; Jeffery C Sellers; Deborah Della Manna; Angelina Londoño Joshi; Hope Amm; J Michael Straughn; Donald J Buchsbaum
Journal:  Gynecol Oncol       Date:  2011-01-05       Impact factor: 5.482

6.  Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response.

Authors:  Ramaswamy Bhuvaneswari; Yik Yuen Gan; Khee Chee Soo; Malini Olivo
Journal:  Mol Cancer       Date:  2009-11-02       Impact factor: 27.401

Review 7.  Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.

Authors:  Anand Rajeswaran; Andreas Trojan; Bernard Burnand; Massimo Giannelli
Journal:  Lung Cancer       Date:  2007-08-27       Impact factor: 5.705

8.  Analysis of cell cycle by flow cytometry.

Authors:  Piotr Pozarowski; Zbigniew Darzynkiewicz
Journal:  Methods Mol Biol       Date:  2004

Review 9.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

10.  Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.

Authors:  Govardhanan Nagaiah; Akm Hossain; Colin J Mooney; James Parmentier; Scot C Remick
Journal:  J Oncol       Date:  2011-06-12       Impact factor: 4.375

View more
  3 in total

1.  Evaluation of synergistic effects of sulforaphene with photodynamic therapy in human cervical cancer cell line.

Authors:  R Biswas; A Mondal; S Chatterjee; J C Ahn
Journal:  Lasers Med Sci       Date:  2016-08-03       Impact factor: 3.161

2.  Enhanced photocytotoxicity of curcumin delivered by solid lipid nanoparticles.

Authors:  Shan Jiang; Rongrong Zhu; Xiaolie He; Jiao Wang; Mei Wang; Yechang Qian; Shilong Wang
Journal:  Int J Nanomedicine       Date:  2016-12-22

3.  Evaluation for Synergistic Effects by Combinations of Photodynamic Therapy (PDT) with Temoporfin (mTHPC) and Pt(II) Complexes Carboplatin, Cisplatin or Oxaliplatin in a Set of Five Human Cancer Cell Lines.

Authors:  Carsten Lange; Patrick J Bednarski
Journal:  Int J Mol Sci       Date:  2018-10-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.